Clinical Edge Journal Scan

Elevated Risk for PsA in Patients With Psoriasis and Arthralgia


 

Key clinical point: Patients with psoriasis who had subclinical psoriatic arthritis (PsA) based on the presence of arthralgia had a higher likelihood of developing PsA than those with only psoriasis.

Major finding: At a mean follow-up of 33 months, 80.9% of patients had subclinical PsA, with the incidence rate of new-onset PsA being 7.7 per 100 patients-years in this group and the most predominant presentation being peripheral arthritis (82.1%). The risk of developing PsA was significantly higher in patients with subclinical PsA vs psoriasis (hazard ratio, 11.7; P = .016).

Study details: This study included 384 patients with psoriasis from two European cohorts of whom 56 patients developed new-onset PsA.

Disclosures: This study did not disclose any specific funding. Six authors declared being consultants for or having other ties with various sources. The other authors declared no conflict of interests.

Source: Zabotti A, Fagni F, Gossec L, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: Exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10:e004314. Source

Recommended Reading

Bone Erosions Highly Prevalent in Early, Untreated PsA
MDedge Rheumatology
Real World Study Confirms Efficacy of Risankizumab in PsA
MDedge Rheumatology
Meta-Analysis Identifies IL17A Inhibitor as a Better Treatment Option in Biologic-Naive Patients with PsA
MDedge Rheumatology
Clinical Characteristics of Severe PsA
MDedge Rheumatology
Second Ustekinumab Biosimilar Gets FDA Approval
MDedge Rheumatology
Combined Pediatric Derm-Rheum Clinics Supported by Survey Respondents
MDedge Rheumatology
Commentary: Comparisons Among PsA Therapies, May 2024
MDedge Rheumatology
Poor Use of ICD-10 Rheumatology Codes Suggests New Approach Needed for ICD-11 Adoption
MDedge Rheumatology
Secukinumab Safe and Effective in Challenging-to-Treat Patients With PsA
MDedge Rheumatology
Risankizumab Shows Long-Term Efficacy in PsA Regardless of Baseline Characteristics
MDedge Rheumatology